Skip to main content
×
×
Home

Information:

  • Access
  • Cited by 26
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Szigeti, Balázs Winstock, Adam R Erritzoe, David and Maier, Larissa J 2018. Are ecstasy induced serotonergic alterations overestimated for the majority of users?. Journal of Psychopharmacology, Vol. 32, Issue. 7, p. 741.

    Sessa, Ben 2018. Handbuch Psychoaktive Substanzen. p. 83.

    Sessa, Ben 2017. Why MDMA therapy for alcohol use disorder? And why now?. Neuropharmacology,

    Sessa, Ben 2017. Handbuch Psychoaktive Substanzen. p. 1.

    Anneken, John H. Collins, Stuart A. Yamamoto, Bryan K. and Gudelsky, Gary A. 2016. Neuropathology of Drug Addictions and Substance Misuse. p. 406.

    Roberts, Carl. Alexander Jones, Andrew and Montgomery, Catharine 2016. Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users. Neuroscience & Biobehavioral Reviews, Vol. 63, Issue. , p. 158.

    Vegting, Yosta Reneman, Liesbeth and Booij, Jan 2016. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology, Vol. 233, Issue. 19-20, p. 3473.

    Sessa, Ben 2016. Handbuch Psychoaktive Substanzen. p. 1.

    Laursen, Helle Ruff Henningsson, Susanne Macoveanu, Julian Jernigan, Terry L Siebner, Hartwig R Holst, Klaus K Skimminge, Arnold Knudsen, Gitte M Ramsoy, Thomas Z and Erritzoe, David 2016. Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use. Journal of Psychopharmacology, Vol. 30, Issue. 12, p. 1296.

    McCann, Una D. and Ricaurte, George A. 2014. The Effects of Drug Abuse on the Human Nervous System. p. 475.

    Guimarães dos Santos, Rafael 2013. Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology. Journal of Psychoactive Drugs, Vol. 45, Issue. 1, p. 68.

    Bosch, Oliver G. Wagner, Michael Jessen, Frank Kühn, Kai-Uwe Joe, Alexius Seifritz, Erich Maier, Wolfgang Biersack, Hans-Jürgen Quednow, Boris B. and Sensi, Stefano L. 2013. Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users. PLoS ONE, Vol. 8, Issue. 4, p. e61234.

    Boulougouris, Vasileios Malogiannis, Ioannis Lockwood, George Zervas, Iannis and Di Giovanni, Giuseppe 2013. Serotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy. Experimental Brain Research, Vol. 230, Issue. 4, p. 605.

    Urban, Nina BL Girgis, Ragy R Talbot, Peter S Kegeles, Lawrence S Xu, X Frankle, W Gordon Hart, Carl L Slifstein, Mark Abi-Dargham, Anissa and Laruelle, Marc 2012. Sustained Recreational Use of Ecstasy Is Associated with Altered Pre and Postsynaptic Markers of Serotonin Transmission in Neocortical Areas: A PET Study with [11C]DASB and [11C]MDL 100907. Neuropsychopharmacology, Vol. 37, Issue. 6, p. 1465.

    Flavel, Stanley C. Koch, Jenna D. White, Jason M. Todd, Gabrielle and Chen, Robert 2012. Illicit Stimulant Use in Humans Is Associated with a Long-Term Increase in Tremor. PLoS ONE, Vol. 7, Issue. 12, p. e52025.

    Meyer, Jeffrey 2012. The Neurobiological Basis of Suicide. Vol. 20122732, Issue. , p. 159.

    Saulin, Anne Savli, Markus and Lanzenberger, Rupert 2012. Serotonin and molecular neuroimaging in humans using PET. Amino Acids, Vol. 42, Issue. 6, p. 2039.

    Murphy, Philip N. Bruno, Raimondo Ryland, Ida Wareing, Michele Fisk, John E. Montgomery, Catharine and Hilton, Joanne 2012. The effects of ‘ecstasy’ (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses. Human Psychopharmacology: Clinical and Experimental, Vol. 27, Issue. 2, p. 113.

    Tai, Yen F Hoshi, Rosa Brignell, Catherine M Cohen, Lisa Brooks, David J Curran, H Valerie and Piccini, Paola 2011. Persistent Nigrostriatal Dopaminergic Abnormalities in Ex-Users of MDMA (‘Ecstasy’): An 18F-Dopa PET Study. Neuropsychopharmacology, Vol. 36, Issue. 4, p. 735.

    Maron, Eduard Tõru, Innar Hirvonen, Jussi Tuominen, Lauri Lumme, Ville Vasar, Veiko Shlik, Jakov Nutt, David J Helin, Semi Någren, Kjell Tiihonen, Jari and Hietala, Jarmo 2011. Gender differences in brain serotonin transporter availability in panic disorder. Journal of Psychopharmacology, Vol. 25, Issue. 7, p. 952.

    ×

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Brain serotonin transporter binding in former users of MDMA (‘ecstasy’)
        Available formats
        ×
        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Brain serotonin transporter binding in former users of MDMA (‘ecstasy’)
        Available formats
        ×
        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Brain serotonin transporter binding in former users of MDMA (‘ecstasy’)
        Available formats
        ×
Export citation

Abstract

Background

Animal experimental studies have prompted concerns that widespread use of 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’) by young people may pose a major public health problem in terms of persistent serotonin neurotoxicity.

Aims

To determine the status of brain serotonin neurons in a group of abstinent MDMA users.

Method

We assessed the integrity of brain serotonin neurons by measuring serotonin transporter (SERT) binding using positron emission tomography (PET) and [11C]DASB in 12 former MDMA users, 9 polydrug users who had never taken MDMA and 19 controls who reported no history of illicit drug use.

Results

There was no significant difference in the binding potential of [11C]DASB between the groups in any of the brain regions examined.

Conclusions

To the extent that [11C]DASB binding provides an index of the integrity of serotonin neurons, our findings suggest that MDMA use may not result in long-term damage to serotonin neurons when used recreationally in humans.

Footnotes

Declaration of interest

P.G. has received occasional consultancy for GlaxoSmithKline (GSK), MERCK, Pfizer and GE Healthcare. P.C. is an MRC Clinical Scientist. N.V.M. is a GSK employee and holds GSK shares. Z.B. has served on the speakers' panel of BMS, AstraZenaca and Janssen.

The compound 3,4-methylenedioxymethamphetamine (MDMA), popularly known as ‘ecstasy’, is the most commonly misused controlled drug after cannabis among young people in Europe. 1 Its use poses a significant public health problem due to its known acute toxicity (hyperthermia and related medical complications). 2 However, there has also been concern about the possible long-term neurotoxic effects of MDMA on brain serotonin neurons.

The neuronal serotonin transporter (SERT) is present in the serotonin (5-HT) synapse as well as along the 5-HT axons. 3 Serotonin transporter is considered to be one of the markers of the integrity of serotonin neurons and has been validated in animal models of MDMA neurotoxicity. 46 Studies in rodents and non-human primates suggest long-lasting reductions in SERT availability after single and multiple administrations. 79 In humans, imaging studies using either positron emission tomography (PET) or single photon emission computed tomography (SPECT) have also shown lowered brain SERT binding in current MDMA users but it is uncertain for how long this abnormality might persist following abstinence. The aim of the present study was to investigate SERT binding, using PET in conjunction with [11C]DASB, a highly specific radioligand for the human SERT, in former MDMA users who had been abstinent from the drug for at least 1 year.

Method

Participants

Three groups of male volunteers were recruited via newspaper or magazine advertisement and word of mouth. The groups comprised 12 former MDMA users who had taken the drug on a regular basis (at least 25 occasions) previously but who had not taken it for at least 1 year, although they continued to use other recreational drugs (the MDMA group), 9 polydrug users who were using a range of recreational drugs matched with the former MDMA users but who reported never having taken MDMA (the polydrug group), and 19 drug-naive controls who reported no history of illicit drug use (the drug-naive group). We chose to study a polydrug (i.e. minus MDMA) user group so that in the event of a change of 5-HT transporter (5-HTT) binding in the MDMA group, the contribution of concomitant polydrug use could be examined.

Potential participants were diagnostically assessed by experienced clinical psychiatrists (S.S., Z.B.) using the Structured Clinical Interview for DSM–IV Axis I Disorders. 10 Inclusion criteria for all groups were male, aged 25–60, no history of prescribed psychotropic medication, no history of major psychiatric or neurological problems, no history of drug dependence, not having drunk more that three units of alcohol in the 24 h prior to testing and no use of recreational drugs for at least 3 days prior to testing. All participants filled in questionnaire measures for depression (Beck Depression Inventory, BDI), 11 anxiety (Spielberger Anxiety Inventory, STAI), 12 neuroticism (Eysenck score) 13 or premorbid IQ (Spot-the-Word Test). 14 All participants gave full written informed consent for the study and were paid an honorarium for their participation. The study was approved by the research ethics committee at Hammersmith Hospital, London, and the Administration of Radioactive Substances Advisory Committee, UK.

A semi-structured drug-use history interview schedule was completed by all participants. The MDMA and polydrug groups were well matched in terms of drug and alcohol use (Table 1). Each participant from the MDMA and polydrug groups gave a urine sample on the day of the PET scan that was screened for MDMA, cocaine, amphetamine, opiates or benzodiazepines. Individuals with a positive urine screen for any of these substances were excluded from the study. Participants also gave hair samples that were tested for MDMA, cocaine and amphetamine; individuals testing positive for MDMA (n=2) were subsequently excluded from the analysis. The average hair sample covered a period of 2.7 months (s.d.=0.9). Matched drug-naive individuals were rigorously screened at interview for drug and alcohol history by experienced psychiatrists and a random 50% provided urine and hair samples that were tested to confirm no illicit drug use.

Table 1 Mean (s.d.) and range of drug use reported by former MDMA users and polydrug controls

MDMA group, n=12 Polydrug group, n=9
Mean (s.d.) Range Mean (s.d.) Range
3,4-methylenedioxymethamphetamine (MDMA)
    Time since last use, years 2.74 (1.46) 390-1825a - -
    Age of first use, years 18.08 (1.9) 14-22 - -
    Length of regular use, years 4.33 (2.8) 1.5-10 - -
    Frequency of use, days per month 4.75 (3.1) 1-12 - -
    Number of tablets used in a typical session 2.75 (1.9) 1-8 - -
    Lifetime occasions used 243.75 (244.4) 60-864 - -
Cannibis
    Time since last use, days 249.14 (446.5) 3-1460 295.89 (620.30) 3-1825
    Age of first use, years 16.36 (1.9) 14-20 17.78 (4.0) 12-25
    Length of regular use, years 8.93 (3.4) 3.8-14 14.39 (13.0) 1.5-38
    Frequency of use, days per month 18.41 (11.00) 2-30 15.44 (11.84) 1-30
    Dose, ounces per month 0.60 (0.80) 0.3-5 1.12 (1.34) 0.1-2
Amphetamine
    Time since last use, days 2391.82 (1689.2) 365-6205 1744.63 (1529.36) 30-3650
    Age of first use, years 18.75 (2.49) 15-24 20.88 (5.59) 16-33
    Length of regular use, years 1.71 (0.76) 1-3 4.75 (7.1) 1-22
    Frequency of use, days per month 4.57 (6.88) 1-20 7.69 (8.84) 1-25
    Dose, grams per session 1.64 (1.31) 1-4.5 1.30 (1.93) 0.1-6
Cocaine
    Time since last use, days 886.05 (927.63) 3-2730 684.14 (1316.4) 4-3650
    Age of first use, years 20.77 (1.69) 18-23.5 22.33 (4.76) 17-30
    Length of regular use, years 3.60 (1.95) 1-6 4.83 (2.93) 2-10
    Frequency of use, days per month 5.47 (8.18) 2-20 3.5 (4.20) 1-12
    Dose, grams per session 2.35 (2.79) 0.3-6.5 0.67 (0.49) 0.3-1.5
Lysergic acid diethylamide (LSD)
    Time since last use, days 1948.2 (1479.71) 30-4380 5108.5 (2295.8) 2920-8000
    Age of first use, years 17.13 (1.64) 14-19 19.25 (2.99) 16-23
    Length of regular use, years 1.90 (1.47) 0.5-4 2.67 (2.08) 1-5
    Frequency of use, days per month 4.90 (3.78) 1-10 1.67 (0.58) 1-2
    Dose, trips per session 2.10 (0.96) 1-3.5 1.00 (0.00) 1-1
Alcohol
    Time since last use, days 4.9 (5.4) 1-21 2.9 (2.5) 1-7
    Age at first use, years 14.8 (1.8) 11-17 15.3 (1.9) 12-19
    Length of regular use, years 10.8 (2.8) 4.5-15 18.4 (9) 8-31
    Frequency, days per month 8.7 (5.9) 2-20 9.2 (6.6) 2-20
    Dose, units per session 7.2 (2.5) 4-12 8.7 (4.6) 2-16

Radioligand

The radiotracer [11C]DASB was synthesised as previously described. 15 The standard DASB and the precursor desmethyl DASB were obtained from Target Molecules Ltd., Southampton (UK). [11C]DASB was injected into an antecubital vein as a smooth bolus over 30 s. The injected radioactivity dose was between 308 and 563.7 MBq (mean 518.3 MBq, s.d=62). The radiochemical purity of the injected [11C]DASB was high and ranged from 95 to 100% with a mean of 97.6% (s.d.=1.4). The specific activity was on average 75530 MBq·μmol–1 (s.d.=12 5821). The injected mass of total cold DASB varied between 0.15 and 12.2 g with a mean value of 3.5 g (s.d.=2.2).

PET scanning

All PET scans were performed on the high-sensitivity Siemens/CTI scanner ECAT EXACT3D, as described previously. 16 The 90-minute three-dimensional dynamic emission scan following injection of radiotracer was acquired in list mode. In the post-acquisition frame rebinning, 28 time frames of increasing length were generated (30 s background frame prior to the injection, then one 15 s frame, one 5 s frame, one 10 s frame, three 30 s frames, three 60 s frames, three 120 s frames, three 180 s frames, eight 300 s frames and four 450 s frames).

The arterial plasma input function for each scan was derived from continuous online whole blood monitoring (initial 28 min) and ten discrete blood samples, in eight of which the fraction of unmetabolised parent compound was determined. 17 Calculations were performed using Matlab (The MathWorks Inc., Natick, Massachusetts, USA) on Sun Ultra™ 10 workstations (Sun Microsystems, Inc., Santa Clara, California, USA).

Magnetic resonance scans and definition of volumes of interest

All volunteers had a structural T1 magnetic resonance imaging (MRI) scan performed on either 0.5 T (0.5 Apollo system, Marconi Medical Systems, Cleveland, Ohio) (repetition time (TR)=30 s, echo time (TE)=3 s, flip angle=30°, number of signal averages (NSA)=1, voxel dimensions 0.98 mm × 1.65 mm × 1.6 mm, acquisition time=13 min) or 1.5 T (1.5 Eclipse system, Marconi Medical Systems, Cleveland, Ohio) scanners (TR=30 s, TE=3 s, flip angle=30°, NSA=1, voxel dimensions 0.98 mm × 1.6 mm × 1.6 mm, acquisition time=13 min) or 3 T (3T Intera Philips Medical Systems) scanners (TR=9.6 s, TE=4.6 s, flip angle=8°, NSA=1, voxel dimensions 0.94 mm × 0.94 mm × 1.2 mm). The scans were inspected by an independent neuroradiologist and found to be normal.

Magnetic resonance images were resliced to a voxel size of 1 mm × 1 mm × 1 mm; centred on anterior commissure (AC) and aligned to the AC–PC (posterior commissure) line. The MRIs were co-registered to the individual summated PET images using SPM2, which adopts a rigid body transformation using a normalised mutual information method. Regions of interest (ROI) were chosen on the basis of a previous [11C]DASB study by McCann et al; 18 they were: amygdala, caudate, anterior and posterior cingulate cortex, dorsal raphe, frontal cortex, hippocampus, insula, putamen, thalamus and cerebellum (the latter as a reference region). As a result of the difficulties in reliable quantification of [11C]DASB in neocortical regions (relatively low signal:noise ratio), the analysis was restricted to the frontal cortex only. Regions of interest were defined on the co-registered MRI with the help of a probabilistic brain atlas template 19 except for the dorsal raphe. The dorsal raphe region was manually defined as a fixed size region (900 mm3) on the summed PET images of each individual. Standard MNI T1 template (available in the SPM2) was normalised to the co-registered individual MRI and the deformation parameters were applied to the probabilistic atlas. This normalised brain atlas was then resliced to PET space and segmented to obtain PET data from grey matter only. Cerebellar grey matter was used to obtain estimates of the free and non-specific radioligand binding because of the very low density of 5-HTT in the cerebellum. 20 Dynamic PET scans were sampled by applying the individual ROI object maps and regional time–activity curves were created. Time–activity curves were manually quality checked in all the scans.

Quantification of DASB binding

To quantify the binding of [11C]DASB in brain tissue, the graphical analysis of reversible radioligand binding using the plasma input function 21 was applied to obtain regional estimates of the total volume of distribution V T from the slope of the linear part of the plot. 17 The threshold was set at 35 min, i.e. the transformed data from frames 20 to 28 were fitted to a straight line.

Estimates of the binding potential BP ND in target regions of interest were calculated indirectly from the estimated V T in those regions and the V T estimate in the cerebellum, 22

\batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \[\ BP_{ND}=\frac{V_{T}^{\mathrm{target\ region}}}{V_{T}^{\mathrm{reference\ region}}}-1\ \] \end{document}

where BP ND refers to the specific binding compared with the non-displaceable uptake. To also assess [11C]DASB binding on a pixel level, spectral analysis was used to generate parametric maps of VT. 23 A set of 100 basis functions logarithmically spaced between βmin=0.0007/s and βmax=0.1/s was chosen to obtain unbiased estimates of V T for the specific kinetics of [11C]DASB. 17 Individual V T images were then normalised to the standard MNI T1 template and average V T images for the three cohorts were calculated (online Fig. DS1).

Statistical analysis

Statistical analyses were performed using Statistical Package for Social Sciences (SPSS Inc., Chicago, Illinois, USA) version 14 for Windows. Our primary hypothesis was that regional 5-HTT receptor binding potential would be lower in the MDMA group compared with the other two groups. We tested this using a repeated measures analysis of variance (ANOVA) with ‘group’ as the between-participants factor, and ‘region’ (brain regions of interest) as the within-participant factor with age as a covariate. Huynh–Feldt correction was applied as appropriate where the assumption of sphericity was violated (uncorrected degrees of freedom are shown for clarity). Other comparisons were made using one-way ANOVA with post hoc t-tests (two-tailed).

Results

The age was significantly different between the groups (ANOVA F=3.76, d.f.=2,39, P=0.03; Table 1). The polydrug group were older than the other two groups (mean age (range): drug-naive group 30.5 (25–45); MDMA group 28.2 (25–36); polydrug group 35.6 (25–50)). Age was therefore used as a covariate in all further analyses.

SERT binding

There were no significant differences in cerebellar volume of distribution V T (F=0.76, d.f.=2,39, P=0.47) (10.63 (s.d.=1.4) (ml plasma)/(cm3 extravascular tissue) in the drug-naive group; 10.43 (s.d.=2.3) (ml plasma)/(cm3 extravascular tissue) in the MDMA group and 11.36 (s.d.=1.7) (ml plasma)/(cm3 extravascular tissue) in the polydrug group. The injected [11C]DASB dose (one-way ANOVA F=2.18, d.f.=2,39, P=0.13), or [11C]DASB specific activity (F=0.07, d.f.=2,39, P=0.93) was not significantly different between the groups.

The repeated measures ANOVA showed a significant main effect of brain region (F=7.84, d.f.=9,324, P=0.002) but no main effect of group (F=1.22, d.f.=2,36, P=0.31) or region × group interaction (F=0.36, d.f.=18,324, P=0.81). There was no significant main effect of age (F=0.18, d.f.=1,36, P=0.66) or age × region interaction (F=0.37, d.f.=9,324, P=0.65). The mean binding potentials of the three groups in all the ROIs studied are shown in Fig. 1. There were no significant correlations observed between any variables of MDMA use and [11C]DASB binding.

Fig. 1 Binding potential BP ND of [11C]DASB in the drug-naive, MDMA and polydrug groups in different regions of the brain. (a) and (b) error bars represent within-group standard deviation.

We found no significant differences between the MDMA group compared with the polydrug group in any of the illicit drugs studied, with or without Bonferroni correction for multiple comparisons. There were no significant group differences in depression (BDI), anxiety (STAI), neuroticism (Eysenck score) or premorbid IQ (Spot-the-Word Test) (P>0.2).

Discussion

The main finding of this study is that former MDMA users abstinent from MDMA for a minimum of 1 year show no differences in SERT availability compared with drug-naive controls or matched polydrug controls who had never used MDMA. The results can be explained in two ways. Either former MDMA users do not show any difference in SERT binding during MDMA use and this remains the case after abstinence, or a period of prolonged abstinence from MDMA use allows a recovery of SERT availability.

The second explanation would clearly seem more likely given the large body of preclinical and some clinical studies consistently showing neurotoxic effects of MDMA on brain serotonin transporters with current MDMA use. 8,24 Thus, our findings support and extend the results of previous studies indicating possible recovery of serotonin transporters following cessation of MDMA use. 2528

The power analysis suggests that with this study population we would have been able to detect a change of 15–20% in the binding potential estimates in most of the brain regions studied at 80% power and P<0.05. This suggests that our study was sufficiently powered to detect differences of the order usually reported between current MDMA users and drug-naive controls in ligand imaging studies of the 5-HTT.

As a result of the limitations of retrospective design of the study, it is difficult to control for pre-existing differences in SERT binding between the MDMA and control groups. However, Thomasius et al 27 recently followed up a series of both current and former MDMA users twice at 9- to 12-month intervals after original testing assessing 5-HTT binding with PET using [11C](+)McN5652. The former users showed no significant differences in 5-HTT binding compared with control participants on any of the test sessions with no changes in binding in former users over time. However, current MDMA users had reduced SERTat baseline (compared with the drug-naive control group) but showed a slight increase in SERT in mid-brain binding over follow-up, despite the fact they had continued to use MDMA, albeit in reduced quantities. The authors, combining these results, conclude that the effects of MDMA use on SERT availability may be reversible.

However, preclinical research does suggest that MDMA can cause persisting serotonergic damage. For example, Hatzidimitriou et al 9 investigated SERT densities in primates 7 years after MDMA administration and found that many brain areas, especially the neocortex, hippocampus, amygdala and cingulate cortex still showed reductions in SERT, whereas the globus pallidus had become hyper-innervated and showed greater levels of 5-HT axonal markers than control animals. Fischer et al 29 reported similar results, and found that altered re-innervation patterns were more pronounced in primates than in rats.

This contrast between the animal and the human studies could be explained by several factors. It is possible that a subcutaneous dose regimen of 5 mg/kg twice daily for 4 consecutive days, used for example in Hatzidimitriou et al, 9 has higher neurotoxicity potential than the oral doses used recreationally by the former users in the present study. Although the authors claim interspecies scaling indicates their doses could lie in the range of human recreational doses, a recent study found no changes in serotonergic function in rhesus monkeys that self-administered MDMA 30 at a rate of 2–4 mg/kg three times per week – a dose regime more comparable to the way in which recreational MDMA users ‘self-administer’ the drug. 31 Alternatively, the longitudinal study of Thomasius et al 27 could indicate a greater resilience to MDMA-induced serotonergic injury in humans compared with non-human primates.

It is important to note that in this study we included only males. Reneman et al 32 suggest from a small-scale study that females are more susceptible to MDMA-related neurotoxicity than males. It is therefore possible that in female participants we might have detected a persistent effect of MDMA to lower [11C]DASB binding to the 5-HTT. Another limitation is that we only measured SERT binding and normal availability of SERT binding sites might not exclude changes in other aspects of 5-HT function, for example 5-HT synthesis. Finally, it is possible that normal levels of SERT binding might conceal altered patterns of 5-HT innervation consequent upon neuronal damage and regeneration.

In summary, this study supports previous research indicating no differences in [11C]DASB binding to the serotonin transporter in former MDMA users compared with drug-naive controls indicating possible recovery of 5-HT function after cessation of MDMA.

Funding

This study was supported by the Medical Research Council (MRC). R.H. was supported by an MRC studentship.

References

1 United Nations International Narcotics Control Board. Annual Report 2006. United Nations, 2007.
2 Hall, AP, Henry, JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96: 678–85.
3 Zhou, FC, Tao-Cheng, JH, Segu, L, Patel, T, Wang, Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 1998; 805: 241–54.
4 Battaglia, G, Yeh, SY, O'Hearn, E, Molliver, ME, Kuhar, MJ, De Souza, EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242: 911–6.
5 Ricaurte, GA, Yuan, J, McCann, UD. (+/-)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42: 510.
6 Szabo, Z, McCann, UD, Wilson, AA, Scheffel, U, Owonikoko, T, Mathews, WB, et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002; 43: 678–92.
7 Easton, N, Marsden, CA. Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194210.
8 Green, AR, Mechan, AO, Elliott, JM, O'Shea, E, Colado, MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 2003; 55: 463508.
9 Hatzidimitriou, G, McCann, UD, Ricaurte, GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999; 19: 5096–107.
10 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV Axis I Disorders – Clinician Version (SCID–CV). American Psychiatric Press, 1997.
11 Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71.
12 Spielberger, CE, Garsuch, RL, Lushene, RE. Manual for the State–Trait Anxiety Inventory. Consulting Psychologists Press, 1970.
13 Eysenck, HJ, Eysenck, SBG. Manual of the Eysenck Personality Scales (EPS Adult). Hodder and Stoughton, 1991.
14 Baddeley, A, Emslie, H, Nimmo Smith, I. The Spot-the-Word Test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 1993; 32: 5565.
15 Wilson, AA, Ginovart, N, Schmidt, M, Meyer, JH, Threlkeld, PG, Houle, S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000; 43: 3103–10.
16 Bhagwagar, Z, Murthy, N, Selvaraj, S, Hinz, R, Taylor, M, Fancy, S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry 2007; 164: 1858–65.
17 Hinz, R, Selvaraj, S, Murthy, NV, Bhagwagar, Z, Taylor, M, Cowen, PJ, et al. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J Cereb Blood Flow Metab 2008; 28: 1478–90.
18 McCann, UD, Szabo, Z, Seckin, E, Rosenblatt, P, Mathews, WB, Ravert, HT, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005; 30: 1741–50.
19 Hammers, A, Koepp, MJ, Free, SL, Brett, M, Richardson, MP, Labbé, C, et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp 2002; 15: 165–74.
20 Kish, SJ, Furukawa, Y, Chang, LJ, Tong, J, Ginovart, N, Wilson, A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005; 32: 123–8.
21 Logan, J, Fowler, JS, Volkow, ND, Wolf, AP, Dewey, SL, Schlyer, DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740–7.
22 Innis, RB, Cunningham, VJ, Delforge, J, Fujita, M, Gjedde, A, Gunn, RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533–9.
23 Cunningham, VJ, Jones, T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 1523.
24 Reneman, L, de Win, MM, van den Brink, W, Booij, J, den Heeten, GJ. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 2006; 20: 164–75.
25 Buchert, R, Thomasius, R, Wilke, F, Petersen, K, Nebeling, B, Obrocki, J, et al. A voxel-based PET investigation of the long-term effects of “Ecstasy” consumption on brain serotonin transporters. Am J Psychiatry 2004; 161: 1181–9.
26 Reneman, L, Lavalaye, J, Schmand, B, de Wolff, FA, van den Brink, W, den Heeten, GJ, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”): preliminary findings. Arch Gen Psychiatry 2001; 58: 901–6.
27 Thomasius, R, Zapletalova, P, Petersen, K, Buchert, R, Andresen, B, Wartberg, L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006; 20: 211–25.
28 Thomasius, R, Petersen, K, Buchert, R, Andresen, B, Zapletalova, P, Wartberg, L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003; 167: 8596.
29 Fischer, C, Hatzidimitriou, G, Wlos, J, Katz, J, Ricaurte, G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). J Neurosci 1995; 15: 5476–85.
30 Fantegrossi, WE, Woolverton, WL, Kilbourn, M, Sherman, P, Yuan, J, Hatzidimitriou, G, et al. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004; 29: 1270–81.
31 Verheyden, SL, Henry, JA, Curran, HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Hum Psychopharmacol 2003; 18: 507–17.
32 Reneman, L, Booij, J, de Bruin, K, Reitsma, JB, de Wolff, FA, Gunning, WB, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864–9.